Bausch + Lomb Partners with Ripple Therapeutics to Develop Polymer-Free Sustained-Release Ophthalmic Implants
核心洞察
Bausch + Lomb has entered into an evaluation program and licensing option agreement with Ripple Therapeutics to develop sustained-release implants for ophthalmic diseases using polymer-free technology.
Ripple's proprietary Epidel platform chemically engineers drugs into prodrugs that form implants without polymers, enabling zero-order release kinetics through surface erosion and leaving no residue after drug release.
The collaboration follows Ripple's recent partnerships with AbbVie (搜索) for glaucoma (搜索) treatment and Glaukos Corporation for both glaucoma and retinal disease applications.
Bausch + Lomb Corporation (搜索) has announced a strategic collaboration with Ripple Therapeutics Corporation (搜索), a clinical-stage Ontario-based company, to develop sustained-release implants for ophthalmic diseases using innovative polymer-free drug delivery technology. The partnership includes an evaluation program and licensing option agreement that positions both companies to advance next-generation ocular therapeutics.
Ripple's Polymer-Free Drug Delivery Platform
Ripple Therapeutics, founded in 2019, has developed a proprietary technology platform called "Epidel" that represents a significant departure from traditional drug delivery approaches. The platform is based on the discovery that drugs can be chemically engineered into controlled-release prodrugs without relying on polymers, components often associated with inflammation in ocular applications.
The Epidel technology chemically modifies drugs into prodrugs that form the main material of an implant or coating without the use of polymers or additional excipient carriers. These prodrugs can be processed into standalone drug delivery implants, including intravitreal (IVT), intracameral (IC), and micro/nanoparticles, or used as medical device coatings.
Controlled Release Mechanism
The technology operates through a surface erosion mechanism that enables zero-order (sustained) release kinetics. During surface erosion, prodrugs dissolve from the Epidel implant surface in a "highly predictable manner" that allows for engineered tailoring of both drug dose and duration. The prodrug's dose is determined by the implant's surface area, while the duration is based on the implant's diameter.
A key advantage of this controlled release system is that the implant completely disappears once the prodrug is fully released, leaving no residue or potential inflammatory degradation byproducts. This characteristic enables repeat dosing and aims to reduce treatment burden by eliminating the need for drops, reducing injection frequency, and enabling easier management of care for eyecare providers.
Partnership Terms and Scope
Under the collaboration agreement, which reportedly began earlier this year, Bausch + Lomb will fund early-stage feasibility and preclinical evaluation of a selected target molecule. The company also holds an option to license any formulations evaluated under this collaboration, with licensing subject to additional financial terms including milestone payments and royalties.
While specific details about the target ophthalmic disease have not been disclosed, Ripple's portfolio extends to glaucoma (搜索) and retina-based investigational therapeutics, including treatments for age-related macular degeneration (搜索) (AMD), designed as implantable prodrugs.
Strategic Context and Industry Partnerships
This collaboration represents the third major partnership for Ripple Therapeutics within the past 14 months. In September 2024, the company entered into a collaboration with AbbVie (搜索) to develop Ripple's sustained-release drug implant (RTC-620) with bimatoprost for lowering intraocular pressure (搜索) (IOP) in open-angle glaucoma (搜索) and ocular hypertensive patients.
In October 2024, Ripple partnered with Glaukos Corporation to use its platform to create sustained-release implants of targeted active pharmaceutical ingredients (APIs) for both glaucoma (搜索) and retinal diseases.
Clinical Development Status
Ripple Therapeutics has generated preclinical findings for its platform technology, though specific clinical trial data has not yet been disclosed. The company's approach addresses a fundamental challenge in ocular drug delivery, where traditional methods often face limitations related to treatment burden and inflammatory responses from polymer-based systems.
Wendy Neimark, Co-Founder and CTO from Ripple Therapeutics, has been recognized as a speaker at industry conferences focusing on strategies to leverage the speed and innovation of biotech startups alongside the deep experience and resources of established pharmaceutical companies.